Differential Effect of Baseline Adiponectin on All-Cause Mortality in Hemodialysis Patients Depending on Initial Body Mass Index. Long-Term Follow-Up Data of 4.5 Years

Journal of Renal Nutrition

Volumn 23, Issue 1, 2013, Pages 45-56

  Tsigalou, Christina ^a   Chalikias, Georgios ^a   Kantartzi, Konstantina ^a   Tziakas, Dimitrios ^a   Kampouromiti, Georgia ^a   Vargemezis, Vassilis ^a   Konstantinides, Stavros ^a   Ktenidou Kartali, Sofia ^a   Simopoulos, Konstantinos ^a   Passadakis, Ploumis ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; INTERLEUKIN 10; INTERLEUKIN 6;

AGED; ARTICLE; BLOOD; BODY MASS; CHRONIC KIDNEY FAILURE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY;

ADIPONECTIN; AGED; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS;

EID: 84871424758     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.12.007     Document Type: Article

References (35)

1. Kaisar O.M., Johnson D.W., Prins J.B., Isbel N. The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin. Curr Cardiol Rev 2008, 4:287-292.
2. Adamczak M., Chudek J., Wiecek A. Adiponectin in patients with chronic kidney disease. Semin Dial 2009, 22:391-395.
3. Foley R. Clinical epidemiology of cardiovascular disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003, 16:111-117.
4. Menon V., Li L., Wang X., et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006, 17:2599-2606.
5. Becker B., Kronenberg F., Kielstein J.T., et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005, 16:1091-1098. MMKD study group.
6. Drechsler C., Krane V., Winkler K., Dekker F.W., Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009, 76:567-575.
7. Rao M., Li L., Tighiouart H., Jaber B.L., Pereira B.J.G., Balakrishnan V. Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008, 23:2619-2628. HEMO study group.
8. Zoccali C., Postorino M., Marino C., Pizzini P., Cutrupi S., Tripepi G. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J Intern Med 2010, 269:172-181. CREDIT working group.
9. Obermayr R.P., Temml C., Gutjahr G., et al. Body mass index modifies the risk of cardiovascular death in proteinuric chronic kidney disease. Nephrol Dial Transplant 2009, 24:2421-2428.
10. Kwan B.C., Murtaugh M.A., Beddhu S. Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. Clin J Am Soc Nephrol 2007, 2:992-998.
11. Grobbee D.E., Hoes A.W. Modification and interaction. Clinical epidemiology. Principles, Methods and Applications for Clinical Research 2009, 38-48. Jones&Bartlett, London, UK.
12. Heinzl H., Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 1997, 54:201-208.
13. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002, 13:134-141.
14. Díez J.J., Estrada P., Bajo M.A., et al. High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol 2009, 30:244-252.
15. Zoccali C., Tripepi G., Cambareri F., et al. Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. J Ren Nutr 2005, 15:125-130.
16. Díez J.J., Iglesias P., Fernández-Reyes M.J., et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005, 62:242-249.
17. Chitalia N., Raja R.B., Bhandara T., et al. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol 2010, 23:77-84.
18. Ohashi N., Kato A., Misaki T., et al. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med 2008, 47:485-491.
19. Carrero J.J., Cordeiro A.C., Lindholm B., Stenvinkel P. The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 2010, 19:37-42.
20. Costacou T., Orchard T.J. Adiponectin: good, bad, or just plain ugly?. Kidney Int 2008, 74:549-551.
21. Stenvinkel P. Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Ren Nutr 2011, 21:82-86.
22. McAuley P.A., Sui X., Church T.S., Hardin J.W., Myers J.N., Blair S.N. The joint effects of cardiorespiratory fitness and adiposity on mortality risk in men with hypertension. Am J Hypertens 2009, 22:1062-1069.
23. Janssen P.G., Gorter K.J., Stolk R.P., Rutten G.E. Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: the ADDITION Netherlands study. Prim Care Diabetes 2007, 1:69-74.
24. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
25. Li H.Y., Chiu Y.F., Hwu C.M., et al. The negative correlation between plasma adiponectin and blood pressure depends on obesity: a family-based association study in SAPPHIRe. Am J Hypertens 2008, 21:471-476.
26. Trimarchi H., Muryan A., Dicugno M., et al. In hemodialysis, adiponectin, and pro-brain natriuretic peptide levels may be subjected to variations in body mass index. Hemodial Int 2011, 15:477-484.
27. Pannacciulli N., Vettor R., Milan G., et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 2003, 88:1748-1752.
28. Park S.-H., Carrero J.J., Lindholm B., Stenvinkel P. Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol 2009, 72:87-96.
29. Carrero J.J., Nakashima A., Qureshi A.R., et al. Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int 2011, 79:749-756.
30. Pecoits-Filho R., Lindholm B., Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 2002, 17(Suppl 11):28-31.
31. Axelsson J., Heimbürger O., Lindholm B., Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 2005, 15:131-136.
32. Stenvinkel P., Ketteler M., Johnson R.J., et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005, 67:1216-1233.
33. Wellens K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003, 112:1785-1788.
34. Stenvinkel P., Heimbürger O., Lindholm B., Kaysen G.A., Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000, 15:953-960.
35. Zoccali C., Seck S.M., Mallamaci F. Obesity and the epidemiology and prevention of kidney disease: waist circumference versus body mass index. Am J Kidney Dis 2011, 58:157-159.